Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monitoring therapy with gene expression profiling reveals physiological differences in drug action.

S Wölfl1, A Burchert, T C Kroll

  • 1Institut für Pharamzie und Molekulare Biotechnologie, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimerfeld 364, 69120 Heidelberg, Germany. wolfl@uni-hd.de

Current Pharmaceutical Design
|June 8, 2004
PubMed
Summary

Gene expression profiling monitors drug action, comparing imatinib and IFNalpha treatments in CML patients. This approach shows potential for optimizing individual cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.

Leukemia·2026
Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2018
Same author

Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.

European journal of cancer (Oxford, England : 1990)·2017
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial).

Leukemia·2017
Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2017

Area of Science:

  • Biomedical research
  • Molecular biology
  • Pharmacogenomics

Background:

  • Gene expression profiling is a powerful tool for understanding cellular regulation and molecular changes.
  • It has diverse applications in drug research, including target identification, validation, and specificity assessment.

Purpose of the Study:

  • To focus on therapy monitoring using gene expression profiling.
  • To interpret gene expression profiles in the context of physiological drug action differences.
  • To explore the potential for optimizing individual patient therapy.

Main Methods:

  • Analyzing gene expression changes in blood samples from Chronic Myeloid Leukemia (CML) patients.
  • Comparing gene expression effects of imatinib mesylate (a tyrosine kinase inhibitor) with Interferon-alpha (IFNalpha) treatment.

Related Experiment Videos

  • Interpreting observed gene expression profiles in relation to drug action.

    • Main Results:

    • Observed distinct gene expression changes in CML patients treated with imatinib mesylate compared to IFNalpha.
    • Demonstrated the utility of gene expression profiling for differentiating drug effects.
    • Highlighted the potential for personalized medicine through therapy monitoring.

    Conclusions:

    • Gene expression profiling is a valuable method for monitoring drug efficacy and action during therapy.
    • Comparing expression profiles can reveal physiological differences in drug responses.
    • This technique offers a promising avenue for optimizing individual cancer treatment strategies.